## Kerstin Wa Westman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3799118/publications.pdf

Version: 2024-02-01

45 papers 7,325 citations

172207 29 h-index 233125 45 g-index

46 all docs 46 docs citations

46 times ranked

3861 citing authors

#	Article	IF	CITATIONS
1	Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 2022, 37, 1400-1410.	0.4	21
2	FC058: Long-Term Renal Survival of Anca-Associated Vasculitis Patients Included in the Euvas Randomized Clinical Trials. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	1
3	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.4	3
4	Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study. Journal of Rheumatology, 2020, 47, 1229-1237.	1.0	22
5	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Journal of Rheumatology, 2020, 47, 580-588.	1.0	5
6	Living Anonymous Renal Donors Do Not Regret: Intermediate and Long-Term Follow-Up with a Focus on Motives and Psychosocial Outcomes. Annals of Transplantation, 2019, 24, 234-241.	0.5	17
7	Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis. European Journal of Rheumatology, 2018, 5, 153-159.	1.3	1
8	Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. Rheumatology, 2017, 56, kew465.	0.9	24
9	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Research and Therapy, 2017, 19, 129.	1.6	42
10	The European Vasculitis Society 2016 Meeting Report. Kidney International Reports, 2017, 2, 1018-1031.	0.4	21
11	Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open, 2017, 3, e000435.	1.8	33
12	Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data. Rheumatology, 2017, 56, 1894-1901.	0.9	31
13	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2017, 44, 1468-1475.	1.0	47
14	The long-term outcomes of systemic vasculitis. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i60-6.	0.4	29
15	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases, 2015, 74, 1178-1182.	0.5	217
16	Declining Estimated Glomerular Filtration Rate and Its Association with Mortality and Comorbidity Over 10 Years in Elderly Women. Nephron, 2015, 130, 245-255.	0.9	45
17	Outcome and Treatment of Elderly Patients with ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1128-1135.	2.2	75
18	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology, 2015, 54, 471-481.	0.9	104

#	Article	IF	CITATIONS
19	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Annals of the Rheumatic Diseases, 2015, 74, 177-184.	0.5	214
20	Comparison of Phenotype and Outcome in Microscopic Polyangiitis Between Europe and Japan. Journal of Rheumatology, 2014, 41, 325-333.	1.0	83
21	Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1571-1576.	2.2	53
22	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Annals of the Rheumatic Diseases, 2013, 72, 1003-1010.	0.5	183
23	Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney International, 2013, 84, 397-402.	2.6	220
24	Reply. Arthritis and Rheumatism, 2013, 65, 844-844.	6.7	1
25	A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 188, 2030-2037.	0.4	46
26	Brief Report: Longâ€ŧerm outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis and Rheumatism, 2012, 64, 3472-3477.	6.7	117
27	Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Annals of the Rheumatic Diseases, 2012, 71, 955-960.	0.5	348
28	Risk factors for relapse of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis and Rheumatism, 2012, 64, 542-548.	6.7	298
29	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.5	47
30	Long-term patient survival in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2011, 70, 488-494.	0.5	719
31	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	1.5	147
32	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	0.9	89
33	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine, 2010, 363, 211-220.	13.9	1,471
34	Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin. Journal of Immunology, 2009, 182, 7906-7915.	0.4	50
35	Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Annals of Internal Medicine, 2009, 150, 670.	2.0	790
36	Development of comprehensive disease assessment in systemic vasculitis. Postgraduate Medical Journal, 2008, 84, 143-152.	0.9	91

#	Article	IF	CITATIONS
37	Dialysis-linked complaints and burdens of illness on patient and spouse as predictors of survival in end-stage renal disease patients with home hemodialysis: a 10-year follow-up study. Stress and Health, 2004, 20, 29-34.	1.4	8
38	Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. British Journal of Rheumatology, 2003, 43, 174-180.	2.5	107
39	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. New England Journal of Medicine, 2003, 349, 36-44.	13.9	1,239
40	Low individualized growth hormone (GH) dose increased renal and cardiac growth in young adults with childhood onset GH deficiency. Clinical Endocrinology, 2001, 55, 741-748.	1.2	15
41	Recurrent ANCA-associated small vessel vasculitis after transplantation: A pooled analysis. Kidney International, 1999, 56, 1544-1550.	2.6	152
42	Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody: Technical Note. Kidney International, 1998, 53, 1230-1236.	2.6	82
43	Persistent High Prevalence of Thyroid Antibodies after Immunosuppressive Therapy in Subjects with Glomerulonephritis. American Journal of Nephrology, 1998, 18, 274-279.	1.4	7
44	Elevated Plasma Levels of Acute Phase Proteins in Mesangioproliferative Glomerulonephritis, Membranous Nephropathy and IGA Nephropathy. Scandinavian Journal of Urology and Nephrology, 1995, 29, 5-9.	1.4	5
45	DEMONSTRATION AND CLASSIFICATION OF AMYLOIDOSIS IN NEEDLE BIOPSIES OF THE KIDNEYS, WITH SPECIAL REFERENCE TO AMYLOIDOSIS OF THE AAâ€₹YPE. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1987, 95A, 357-363.	0.3	5